Dicerna on Novo's billion-dollar acquisition: Alleged wrongdoing has no hold in reality
US-based biotech firm Dicerna is distancing itself from the suits filed by its shareholders, following the announcement of Novo Nordisk's planned acquisition of the firm.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Claims of alleged wrongdoing have no hold in reality, says Dicerna in a filing sent to the US Securities and Exchange Commission.
This stance has been taken by Dicerna after some shareholders have filed suits against the firm, alleging violations of the US Securities Exchange Act.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
